The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 9)
Rapid Response Innovation Awards, 2012
Tools for early and unambiguous diagnosis of PD are currently missing and disease symptoms are easily mistaken. On the other hand, prompt recognition of PD subjects may increase the chances of therapeutic success. Our preliminary evidence that the level of a trace amine, octopamine, is altered in early PD provides new hopes for better diagnosis and therapy. Our aim is to inves...
MJFF Research Grant, 2012
Promising Outcomes of Original Grant:
Excessive amounts of amyloid in brain tissue are believed to be toxic and cause the neuronal damage that results in dementia. Amyloid deposits can be detected in life using brain scans with the agent PiB. Using PiB brain scans, we found that ~30% of non-demented PD patients have increased amyloid deposits, and that high PiB uptake was associated with declines...
Researchers: John Growdon, PhD
Dyskinesia Challenge, 2012
In our research we aim to identify changes in neuronal circuits that cause motor symptoms in Parkinson's disease (PD) by recording neuronal activity in healthy and in parkinsonian pre-clinical models. We recently discovered that when parkinsonian models experience levodopa-induced dyskinesia this is always associated with high-frequency oscillations in motor areas...
Researchers: Per Fredrik Petersson, PhD
MJFF Research Grant, 2011
A measurement tool which accurately reflects not only motor deficits but also a host of cognitive dysfunctions seen frequently in Parkinson's disease (PD) would improve diagnosis of the disease and identify PD subtypes for more effective tailored treatment strategies.
We propose that an assessment of motor and cognitive deficits in PD together will lea...
Researchers: Norbert Schuff, PhD
Therapeutics Development Initiative, 2011
Lead Optimization and Pharmacological Characterization of Selective mGluR3 PAMs as Novel Neuroprotective Agents for Parkinson's Disease
mGluR3 is a novel target that could lead to neuroprotection through production of GDNF and TGF-beta in striatal neurons. The goals of the current project are first to optimize existing submicromolar and selective leads into candidates for in vivo studies, and second, to characterize the neuroprotective role of these molecules using in vitro models.
Researchers: Stephan Schann, PhD